Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival
Corrado Tarella(A. O. Ordine Mauriziano di Torino), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Giuseppe Gritti(Ospedale Papa Giovanni XXIII), Cristina Boschini(Ospedale Papa Giovanni XXIII), Andrea Rossi, Federica Delaini(Ospedale Papa Giovanni XXIII), Riccardo Bruna(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Daniele Caracciolo(Magna Graecia University), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Marco Ruella(Parker Institute for Cancer Immunotherapy), Angela Gueli(A. O. Ordine Mauriziano di Torino), Daniela Gottardi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Anna Maria Barbui(Ospedale Papa Giovanni XXIII)
Cited by 26
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|616